Skip to main content
Erschienen in: International Journal of Colorectal Disease 7/2018

02.05.2018 | Original Article

Time between suspected and confirmed diagnoses of Crohn’s disease and ulcerative colitis in patients followed in gastroenterological practices in Germany

verfasst von: Karel Kostev, Marcel Konrad, Louis Jacob

Erschienen in: International Journal of Colorectal Disease | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims

The goal of the present study was to analyze the time between suspected and confirmed diagnoses of Crohn’s disease (CD) and ulcerative colitis (UC) in patients followed in gastroenterological practices in Germany.

Methods

The study included individuals who received a suspected diagnosis of CD or UC (index date) and were followed in 47 gastroenterological practices in Germany between January 2007 and December 2016. The main outcome measure of the study was the time between suspected and confirmed diagnoses of CD and UC. Covariables included age, sex, and type of health insurance (private or statutory). A multivariate linear regression model was used to analyze the impact of the different variables on the time between suspected and confirmed diagnoses of CD and UC.

Results

The study included 2657 patients with a suspected diagnosis of CD and UC between 2007 and 2016. The mean age was 39.7 (SD 15.9) and 41.3 (16.8) in the CD and UC groups, respectively. Median time between suspected and confirmed diagnoses was 46 days in the CD group and 43 days in the UC group. Median time ranged from 8 to 112 days in the different gastroenterology practices and was significantly shorter in individuals with private health insurance coverage than in those with statutory health insurance.

Conclusions

Median time between suspected and confirmed diagnoses of CD or UC was around 45 days in patients followed in gastroenterological practices in Germany. Health insurance was the only factor to have a significant impact on this time.
Literatur
3.
Zurück zum Zitat Stark R, König H-H, Leidl R (2006) Costs of inflammatory bowel disease in Germany. PharmacoEconomics 24:797–814CrossRefPubMed Stark R, König H-H, Leidl R (2006) Costs of inflammatory bowel disease in Germany. PharmacoEconomics 24:797–814CrossRefPubMed
4.
Zurück zum Zitat D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet Lond Engl 371:660–667. https://doi.org/10.1016/S0140-6736(08)60304-9 CrossRef D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet Lond Engl 371:660–667. https://​doi.​org/​10.​1016/​S0140-6736(08)60304-9 CrossRef
5.
Zurück zum Zitat Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ (2011) Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141:1194–1201. https://doi.org/10.1053/j.gastro.2011.06.054 CrossRefPubMed Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ (2011) Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141:1194–1201. https://​doi.​org/​10.​1053/​j.​gastro.​2011.​06.​054 CrossRefPubMed
6.
Zurück zum Zitat Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM, Swiss IBD Cohort Study Group (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18:496–505. https://doi.org/10.1002/ibd.21719 CrossRefPubMed Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM, Swiss IBD Cohort Study Group (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18:496–505. https://​doi.​org/​10.​1002/​ibd.​21719 CrossRefPubMed
9.
Zurück zum Zitat Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, Giannarelli D, Massari A, Monterubbianesi R, Lenti MV et al (2017) The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: an Italian multicentre study. J Crohns Colitis 11:975–980. https://doi.org/10.1093/ecco-jcc/jjx041 CrossRefPubMed Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, Giannarelli D, Massari A, Monterubbianesi R, Lenti MV et al (2017) The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: an Italian multicentre study. J Crohns Colitis 11:975–980. https://​doi.​org/​10.​1093/​ecco-jcc/​jjx041 CrossRefPubMed
11.
Zurück zum Zitat Ricciuto A, Fish JR, Tomalty DE, Carman N, Crowley E, Popalis C, Muise A, Walters TD, Griffiths AM, Church PC (2017) Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn’s disease and associated with decreased height. Arch Dis Child. https://doi.org/10.1136/archdischild-2017-313060 Ricciuto A, Fish JR, Tomalty DE, Carman N, Crowley E, Popalis C, Muise A, Walters TD, Griffiths AM, Church PC (2017) Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn’s disease and associated with decreased height. Arch Dis Child. https://​doi.​org/​10.​1136/​archdischild-2017-313060
12.
Zurück zum Zitat Dombrowski S, Kostev K (2017) Use of electronic medical records in the epidemiological research [internet]. Cuvillier Verlag Dombrowski S, Kostev K (2017) Use of electronic medical records in the epidemiological research [internet]. Cuvillier Verlag
13.
Zurück zum Zitat Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626CrossRefPubMed Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626CrossRefPubMed
14.
Zurück zum Zitat Schiffner R, Kostev K, Gothe H (2016) Do patients with lactose intolerance exhibit more frequent comorbidities than patients without lactose intolerance? An analysis of routine data from German medical practices. Ann Gastroenterol 29(2):174–179CrossRefPubMedPubMedCentral Schiffner R, Kostev K, Gothe H (2016) Do patients with lactose intolerance exhibit more frequent comorbidities than patients without lactose intolerance? An analysis of routine data from German medical practices. Ann Gastroenterol 29(2):174–179CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kostev K, Winiarski M, Schüller L, Sesterhenn AM, Jacob L (2018) Frequency of thyroid-stimulating hormone monitoring in patients after thyroidectomy: a retrospective study in primary care practices in Germany. Exp Clin Endocrinol Diabetes. https://doi.org/10.1055/s-0044-100038 Kostev K, Winiarski M, Schüller L, Sesterhenn AM, Jacob L (2018) Frequency of thyroid-stimulating hormone monitoring in patients after thyroidectomy: a retrospective study in primary care practices in Germany. Exp Clin Endocrinol Diabetes. https://​doi.​org/​10.​1055/​s-0044-100038
Metadaten
Titel
Time between suspected and confirmed diagnoses of Crohn’s disease and ulcerative colitis in patients followed in gastroenterological practices in Germany
verfasst von
Karel Kostev
Marcel Konrad
Louis Jacob
Publikationsdatum
02.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 7/2018
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-018-3068-9

Weitere Artikel der Ausgabe 7/2018

International Journal of Colorectal Disease 7/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.